The efficacy and safety analysis of Peg-IFN/RBV/Vitamin D3 therapy for liver cirrhosis with hepatitis c persistent infection: RCT Study

The efficacy and safety analysis of Peg-IFN/RBV/Vitamin D3 therapy for liver cirrhosis with hepatitis c persistent infection: RCT Study - LCVID STUDY

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007400

Enrollment

Registered

2012-03-01

Start date

2012-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver cirrhosis with hepatitis c persistent infection

Interventions

Peg-IFN/RBV/Vitamin D3 Peg-IFN/RBV

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Over 20 years old LC-C WBC>3000 Neut>1500 PLT>75000 Hb>12

Exclusion criteria

Exclusion criteria: Pregnant Drug allergy Hear Disease Abnormal Hb Renal Failure Sever Liver Disease Autoimmune Hepatitis etc.

Design outcomes

Primary

Measure	Time frame
SVR rate	—

Countries

Japan

Contacts

Public ContactYasuteru Kondo

Tohoku University Hospital Gastroenterology

yasuteru@ebony.plala.or.jp022-717-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026